Leadership in Science Award | Aplastic Anemia and MDS International Foundation

Leadership in Science Award

Recipients, nominated by the Foundation’s Medical Advisory Board, are selected for their unique contributions to bone marrow failure disease treatment or research.

2015 David Steensma, MD

Associate Professor of Medicine, Harvard Medical School

2014 Alan List, MD

President and CEO, Moffitt Cancer Center

President and Chief Executive Officer of Moffitt Cancer Center, Dr. List is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the
U.S. Food and Drug Administration and approval for the treatment of patients with MDS and multiple myeloma. This work transformed the natural history of MDS from a premalignant condition that progressed to malignancy requiring aggressive treatment to a condition managed in the outpatient setting with oral agents.

A member of the AAMDSIF Medical Advisory board, he is the author of more than nearly 300 peer-reviewed articles and the Clinician’s Manual on Myelodysplastic Syndromes (2008). He is an active member of the American Society of Clinical Oncology; American Society of Hematology; American Association for Cancer Research; International Society for Experimental Hematology; JP McCarthy Foundation Medical Advisory Committee; and the Southwestern Oncology Group. Dr. List is also a frequent presenter at AAMDSIF conferences, and appears on AA&MDSIF webinars.

2013 Mikkael A. Sekeres, MD, MS

Associate professor of medicine and Director of the Leukemia Program, Cleveland Clinic Taussig Cancer Institute

Dr. Sekeres is associate professor of medicine and Director of the Leukemia Program, Department of Hematologic Oncology and Blood Disorders with the Cleveland Clinic Taussig Cancer Institute, Ohio. He earned a medical degree and a master’s in clinical epidemiology from the University of Pennsylvania School of Medicine. He completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital and a fellowship in hematology-oncology at the Dana-Farber Cancer Institute in Boston. A frequent speaker and presenter for AAMDSIF patient and family conferences and webinars, and webcasts and videos for both patients and health professionals, he is co-chair of the AAMDSIF medical advisory board (MAB), and also co-chair of the MDS Clinical Research Consortium.

2010 Jaroslaw Maciejewski, MD, PhD

Chairman of Translational Hematology and Oncology Research at the Cleveland Clinic Taussig Cancer Institute, and a professor of medicine at Lerner College of Medicine at Case Western Reserve University

Dr. Maciejewski is recognized for his leadership in finding better treatments and a cure for bone marrow failure diseases, as well as his commitment to cultivating a new generation of researchers in his lab.  He also provides the highest quality care and compassion to his patients and the AAMDSIF community. His clinical areas of expertise include bone marrow failure syndromes - aplastic anemia, MDS, large granular lymphocyte leukemia, PNH and myeloid malignancies. His research includes the molecular pathogenesis of these disorders and various specific aspects of stem cell biology, genetics, cytogenetics and immunobiology.

2009 Richard Stone, MD

Clinical Director of the Adult Leukemia Program at the Dana-Farber Cancer Institute, Attending physician at Brigham and Women’s Hospital, and Associate Professor of Medicine at Harvard Medical School

Dr. Stone cares for patients with acute and chronic leukemias, myelodysplasia and myeloproliferative disorders. Dr. Stone conducts clinical and translational research with the goal of deriving better outcomes for patients with these disorders. His laboratory research focuses on the mechanism of leukemic cell differentiation, with the ultimate goal of producing new cancer therapies.